
Key Biomarkers in the RGCC Onconomics Plus Report: What They Mean
Onconomics Plus is an advanced personalized oncology assessment developed by RGCC.
In addition to testing the sensitivity of circulating tumor cells to various natural substances and pharmaceutical agents,
it also includes a range of key biomarkers closely associated with tumor behavior.
These biomarkers provide vital insights for designing personalized support strategies, risk evaluation, and ongoing monitoring.